Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment‐resistant schizophrenia, even in 22qDS.
Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness / Accinni, Tommaso; Frascarelli, Marianna; Ghezzi, Francesco; Panzera, Alessia; Buzzanca, Antonino; Fanella, Martina; DI BONAVENTURA, Carlo; Carlone, Luca; Girardi, Nicoletta; Pasquini, Massimo; DI FABIO, Fabio. - In: CLINICAL CASE REPORTS: OPEN ACCESS. - ISSN 2582-5038. - (2021). [10.1002/ccr3.4134]
Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness
Tommaso AccinniPrimo
Writing – Original Draft Preparation
;Marianna Frascarelli
Secondo
Writing – Review & Editing
;Francesco GhezziConceptualization
;Alessia PanzeraInvestigation
;Antonino BuzzancaMethodology
;Martina FanellaInvestigation
;Carlo Di BonaventuraSupervision
;Luca CarloneInvestigation
;Nicoletta GirardiInvestigation
;Massimo PasquiniPenultimo
Supervision
;Fabio Di FabioUltimo
Supervision
2021
Abstract
Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment‐resistant schizophrenia, even in 22qDS.| File | Dimensione | Formato | |
|---|---|---|---|
|
Accinni_Clozapine-induced gastroesophageal rumination_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
116.91 kB
Formato
Adobe PDF
|
116.91 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
